Immutep Limited
(NASDAQ: IMMP)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $1.98 | Change: +0.10 | %Change: +5.32% | Volume: 92,052 |
Open: | $ 1.95 | Volume: | 92,052 | |
---|---|---|---|---|
High: | $ 2.04 | Yield(%) | 0.00 | |
Low: | $ 1.91 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 237.47M | |
EPS ($) | n/a | Shares Out: | 126.31M |
% Price Change (last 4 weeks): | -37.44 |
---|---|
% Price Change (last 13 weeks): | -25.98 |
% Price Change (last 26 weeks): | -20.00 |
% Price Change (last 52 weeks): | -12.96 |
% Price Change (year to date): | -21.67 |
Return on Equity (%): | -34.51 |
---|---|
Return on Assets (%): | -31.87 |
Return on Invested Capital (%): | -39.77 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $2.65 |
---|---|
200-day Moving Average: | $2.30 |
Avg. Daily Vol. (last 50 days): | 341,798 |
Avg. Daily Vol. (last 200 days): | 199,665 |
52-wk high: | $3.33 |
52-wk low: | $1.58 |
Bid: | $1.93 |
Ask: | $2.01 |
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.
|
Immutep Limited
Australia Square 264 George Street Level 32, Suite 32.07 Sydney NS 2000 Phone: 61.2.8315.7003 Fax: 61.2.8569.1880 http://www.immutep.com |
Earnings (1year) ($): | -0.26 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 0.76 |
Cash Flow ($): | -0.21 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 2.78 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 13.81 |
---|---|
Current Ratio (x): | 13.81 |
LT Debt/Equity (x): | 0.76 |
Total Debt/Equity (x): | 0.90 |